Collegium Pharmaceutical, Inc.
35.65+0.84 (+2.41%)
Oct 30, 4:00:01 PM EDT · NasdaqGS · COLL · USD
Key Stats
Market Cap
1.12BP/E (TTM)
33.63Basic EPS (TTM)
1.06Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Collegium Pharmaceutical posted solid Q2 FY2025 results, with product revenues hitting $188M, up 29.4% y/y from $145M, fueled by Jornay PM's $33M debut post-September 2024 acquisition alongside Xtampza ER's 18.0% y/y gain to $53M. Gross profit climbed to $108M from $91M y/y, yet operating income dipped 26.1% to $35M as SG&A swelled 70.0% to $74M from integration costs and expanded sales efforts. Diluted EPS fell to $0.34 from $0.52 y/y, reconciled via 39.1M weighted shares including convertible notes adjustment. Cash swelled to $117M with $128M operating cash flow for the half-year, supporting $585M term debt at 9.9% effective rate and $238M convertibles; free cash flow not disclosed in the 10-Q. The Ironshore deal closed September 2024 for $306M cash, adding $635M intangibles amortized over 7.7 years and $14M goodwill. Patent battles with generics loom large.
8-K
Q2 revenues soar 29%
Collegium Pharmaceutical reported Q2 2025 net product revenues of $188.0 million, surging 29% year-over-year, fueled by Jornay PM's record $32.6 million (up 23% in prescriptions) and pain portfolio's $155.4 million (up 7%). The company raised full-year guidance to $745-760 million in revenues and $440-455 million adjusted EBITDA, while authorizing a $150 million share repurchase through 2026. Strong cash generation hit $222.2 million. Yet debt remains a drag on flexibility.
8-K
Collegium launches $150M buyback
Collegium Pharmaceutical's board authorized a $150 million share repurchase program on July 1, 2025, targeting up to that amount of common stock through December 31, 2026. Purchases will occur on the open market, guided by market conditions and share price, funded entirely by existing cash reserves. This signals confidence in the company's value. Yet, execution hinges on volatile markets.
8-K
Shareholders approve 2025 equity plan
Collegium Pharmaceutical's shareholders approved the 2025 Equity Incentive Plan at the May 15, 2025 annual meeting, authorizing up to 3,474,404 shares for stock options, restricted units, and other awards to align employee and director interests with company performance. All eight director nominees were elected, executive pay was endorsed on an advisory basis, and annual say-on-pay votes were favored. This bolsters retention tools amid growth pressures. Plan caps non-employee director awards at $750,000 yearly.
8-K
Collegium launches $25M stock buyback
Collegium Pharmaceutical announced an accelerated share repurchase agreement with Jefferies LLC on May 12, 2025, to buy back $25 million of its common stock as part of a $150 million program authorized in January 2024. The deal delivers 692,281 shares upfront, based on the $28.89 closing price from May 9, with final settlement by Q3 2025. This signals confidence in the company's value. Yet market fluctuations could alter the total shares repurchased.
IPO
Employees
Sector
Industry
ALKS
Alkermes plc
30.82-0.63
AQST
Aquestive Therapeutics, Inc.
6.66+0.18
AYTU
Aytu BioPharma, Inc.
2.21+0.03
BHC
Bausch Health Companies Inc.
6.61+0.71
CBDL
CBD Life Sciences Inc.
0.00-0.00
ELTP
Elite Pharmaceuticals, Inc.
0.61+0.01
HYPMY
Hypera SA
4.60+0.18
PRFX
PainReform Ltd.
1.20-0.06
SUPN
Supernus Pharmaceuticals, Inc.
56.50+0.82
TEVA
Teva Pharmaceutical Industries
20.03-0.20